Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398792 | 1.00 | HCRTR1 (0.88) | HCRTR1HCRTR2 | |
| SCHEMBL1398643 | 1.00 | HCRTR1 (0.88) | HCRTR1HCRTR2 | |
| SCHEMBL1398745 | 0.93 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL1398521 | 0.92 | HCRTR1 (0.86) | HCRTR1HCRTR2 | |
| SCHEMBL1398588 | 0.92 | HCRTR1 (0.86) | HCRTR1HCRTR2 | |
| SCHEMBL1398721 | 0.92 | HCRTR1 (0.86) | HCRTR1HCRTR2 | |
| SCHEMBL1398694 | 0.90 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL1398645 | 0.90 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL1398655 | 0.90 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL1398624 | 0.89 | HCRTR1 (0.81) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | claimed |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-21 | — | — | US | disclosed |
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | GPR180, OXGR1, MLNR | HCRTR1 22/4885HCRTR2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.